Minneapolis-based Orasi Medical said it entered a partnership with a Danish pharmaceutical company to study the effects of central nervous system compounds on the human brain.
Orasi Medical said it will use its software Orasi Index to test Danish company H. Lundbeck A/S drug compounds against a database of brain scans and supporting clinical data on central nervous system drugs and disorders.
Lundbeck has focused its research, development and sales of drugs on disorders such as depression and anxiety, schizophrenia, insomnia, Huntington's, Alzheimer's and Parkinson's disease.
"By identifying the right drug and dose early, we will help companies like Lundbeck develop more effective drugs for the many people that are affected by CNS diseases," said Sarah Haecker, vice president of pharmaceutical business development.
Orasi Medical is licensing technology stemmed from the research of a neuroscience professor at the University of Minnesota.
